Company intelligence / Profile preview
Lineage Cell Therapeutics
Carlsbad, California, USAlineagecell.com ↗
- Ownership
- Public · LCTX
- Development stage
- Phase 2
01
Overview
OpRegen® has shown promising results in a Phase 2a trial under collaboration with Roche/Genentech targeting geographic atrophy in AMD patients. The program has received RMAT designation by FDA. OPC1 is in early phase clinical trials showing initial safety and efficacy signals for spinal cord injury treatment. VAC2 is undergoing Phase I trials as an immuno-oncology candidate[5][6][10].
- Therapeutic areas
- OphthalmologyOncologyNeurology
- Modalities
- Allogeneic ("off-the-shelf") cell therapies derived from pluripotent stem cellsRetinal pigment epithelial cellsOligodendrocyte progenitor cellsAuditory neuronal progenitor cellsPhotoreceptor neural cellsDendritic cell immunotherapies
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
Request access →03
Partnerships
Roche / Genentech collaboration on OpRegen® retinal therapy program[4][5]License agreement with Eterna Therapeutics Inc for gene-edited hypoimmune iPSC lines[4]
04
Financials
- Market cap
- $254.3M
- Total revenue
- $1.1M
- Enterprise value
- $205.8M
Beyond the preview
Go deeper on Lineage Cell Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lineage Cell Therapeutics.